Abstract
Objectives: Long-term safety and tolerability of ACC-001 (vanutide cridificar), an antiamyloid- beta therapeutic vaccine, was evaluated in subjects with mild to moderate Alzheimer’s disease.
Design: Phase 2a extension studies of randomized parent trials were conducted in the United States, European Union, and Japan. Methods: Four immunizations of ACC-001 were administered at the same 3 dose levels (3, 10, and 30 μg) to subjects randomized in the parent studies; ACC-001 was administered with QS-21 adjuvant. Safety, tolerability, and immunogenicity were assessed during active treatment and 6-month follow-up. Results: ACC-001 + QS-21 was well tolerated in the United States (N=110) and European Union (N=50), and Japan (N=53) extension studies; safety profile was similar to that observed in the parent studies, and no new safety signals were identified. Overall, injection site reactions were the most common adverse event in these studies. Anti-amyloid antibody titers were elicited in all groups, with the highest titers observed in subjects who received ACC-001 + QS-21 in both the parent and extension studies. Conclusions: Long-term exposure to ACC-001 + QS-21 was well tolerated in subjects with Alzheimer’s disease, suggesting that side effects do not pose a principal limitation for anti-amyloid active immunotherapy. The highest anti-amyloid-beta IgG titers are elicited during long-term therapy with ACC-001 + QS-21 compared with other regimens.Keywords: Alzheimer’s disease, amyloid-beta, amyloid plaques, antibody, immunotherapy, vaccine.
Current Alzheimer Research
Title:Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Volume: 14 Issue: 7
Author(s): Michael Hull*, Carl Sadowsky, Heii Arai, Ghislaine Le Prince Leterme, Ann Holstein, Kevin Booth, Yahong Peng, Tamotsu Yoshiyama, Hideo Suzuki, Nzeera Ketter, Enchi Liu and J. Michael Ryan
Affiliation:
- Clinic for Geriatric Psychiatry, Center for Psychiatry Emmendingen, Neubronnstraße 25, D-79312 Emmendingen,Germany
Keywords: Alzheimer’s disease, amyloid-beta, amyloid plaques, antibody, immunotherapy, vaccine.
Abstract: Objectives: Long-term safety and tolerability of ACC-001 (vanutide cridificar), an antiamyloid- beta therapeutic vaccine, was evaluated in subjects with mild to moderate Alzheimer’s disease.
Design: Phase 2a extension studies of randomized parent trials were conducted in the United States, European Union, and Japan. Methods: Four immunizations of ACC-001 were administered at the same 3 dose levels (3, 10, and 30 μg) to subjects randomized in the parent studies; ACC-001 was administered with QS-21 adjuvant. Safety, tolerability, and immunogenicity were assessed during active treatment and 6-month follow-up. Results: ACC-001 + QS-21 was well tolerated in the United States (N=110) and European Union (N=50), and Japan (N=53) extension studies; safety profile was similar to that observed in the parent studies, and no new safety signals were identified. Overall, injection site reactions were the most common adverse event in these studies. Anti-amyloid antibody titers were elicited in all groups, with the highest titers observed in subjects who received ACC-001 + QS-21 in both the parent and extension studies. Conclusions: Long-term exposure to ACC-001 + QS-21 was well tolerated in subjects with Alzheimer’s disease, suggesting that side effects do not pose a principal limitation for anti-amyloid active immunotherapy. The highest anti-amyloid-beta IgG titers are elicited during long-term therapy with ACC-001 + QS-21 compared with other regimens.Export Options
About this article
Cite this article as:
Hull Michael*, Sadowsky Carl, Arai Heii, Leterme Le Prince Ghislaine, Holstein Ann, Booth Kevin, Peng Yahong, Yoshiyama Tamotsu, Suzuki Hideo, Ketter Nzeera, Liu Enchi and Ryan Michael J., Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease, Current Alzheimer Research 2017; 14 (7) . https://dx.doi.org/10.2174/1567205014666170117101537
DOI https://dx.doi.org/10.2174/1567205014666170117101537 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Z and Ischemic Stroke
Vascular Disease Prevention (Discontinued) HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Nenatal Drug Induced Nephrotoxicity : Old and Next Generation Biomarkers for Early Detection and Management of Neonatal Drug-Induced Nephrotoxicity, with Special Emphasis on uNGAL and on Metabolomics
Current Medicinal Chemistry From Cerebrospinal Fluid Pulsation to Noninvasive Intracranial Compliance and Pressure Measured by MRI Flow Studies
Current Medical Imaging Relation Between Obstructive Sleep Apnea Syndrome and Resistant Hypertension - The Tip of the Iceberg
Current Respiratory Medicine Reviews Migraine Attack Treatment : A Tailor-made Suit, Not One Size Fits All
Recent Patents on CNS Drug Discovery (Discontinued) Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Relationship Between Body Mass Index and Reproduction
Current Women`s Health Reviews Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia
Current Pharmaceutical Design Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging Interventional Radiology in Paediatrics
Current Pediatric Reviews Human Amniotic Membrane: Clinical Uses, Patents And Marketed Products
Recent Patents on Regenerative Medicine Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Zebrafish As a Genetic Model in Pre-Clinical Drug Testing and Screening
Current Medicinal Chemistry Subject Index to Volume 4
Current Genomics Microarray Profiling Analysis Uncovers Common Molecular Mechanisms of Rubella Virus, Human Cytomegalovirus, and Herpes Simplex Virus Type 2 Infections in ECV304 Cells
Current Molecular Medicine Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Current Pharmaceutical Design